Prognostic Value of Pre-treatment C-reactive protein in Diffuse large B cell lymphoma

Authors

  • Seba Hmdan Tishreen University
  • Firas Hussein Tishreen University
  • Youssef Zreik Tishreen University

Abstract

ABSTRACT

Background: High levels of C-reactive protein (CRP), an acute phase reactant, that has been proven to be associated with decreased clinical outcome in small-scale in Diffuse large B-cell lymphoma (DLBCL). The aim of this study was to evaluate the prognostic impact of pretreatment CRP levels on overall survival (OS) and progression free survival (PFS) of DLBCL patients.

Methods: Data from 117 DLBCL patients, diagnosed and treated between 2010 and 2016 in Tishreen University Hospital, were evaluated retrospectively. The prognostic influence of CRP and other factors, including age, tumor stage, LDH, extra nodal involvement, and international Prognostic Index (IPI) on 5-year OS and 5-year PFS, were studied by Kaplan-Meier curves as well as univariate and multivariate Cox regression models.

Results: Kaplan-Meier curves revealed elevated CRP as a factor for decreased 5-year OS (P=0.002, log-rank test) and PFS in DLBCL patients (P<0.001, Log-rank test). An independent significant association between high CRP levels and poor clinical outcome in multivariate analysis for 5-year OS (HR=6.36, CI95%=1.75-23.13, P=0.005) and for PFS (HR=4.18, CI95%=1.91-9.16, P<0.001). we demonstrated high CRP levels at diagnosis of DLBCL as an independent poor prognostic factor for clinical outcome.

Key Words: Diffuse large B cell lymphoma, C-reactive protein, IPI

Author Biographies

Seba Hmdan, Tishreen University

Postgraduate Student - Department of Internal Medicine (Hematology diseases) -Faculty of Medicine

Firas Hussein, Tishreen University

Associate Professor- Department of Internal Medicine (Hematology diseases) -Faculty of Medicine

Youssef Zreik, Tishreen University

Assistant Professor, laboratory Medicine (Microorganisms)_faculty of medicine

Downloads

Published

2022-06-16

How to Cite

1.
حمدان ص, حسين ف, زريق ي. Prognostic Value of Pre-treatment C-reactive protein in Diffuse large B cell lymphoma. Tuj-hlth [Internet]. 2022Jun.16 [cited 2024Nov.24];44(2):277-89. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/11874

Issue

Vol. 44 No. 2 (2022): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Master student researches

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.